Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:15 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 4,225 matching trials from the local directory fallback.

Filters: Intervention: Placebo Clear all

Conditions: GRIN-related Neurodevelopmental Disorder
Interventions: Placebo, Radiprodil; Drug
Lead sponsor: GRIN Therapeutics, Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more

Conditions: Type 2 Diabetes
Interventions: Empagliflozin 25 MG, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d), Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Menopause
Interventions: High Intensity Exercise, Moderate Intensity Exercise, Nitrate-Depleted Placebo Beetroot Juice, Nitrate-Rich Beetroot Juice; Behavioral · Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aphasia, Primary Progressive
Interventions: Magnetic Resonance Imaging (MRI), Placebo, Propranolol; Device · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Adverse Childhood Experiences
Interventions: Day 1 Assessments, Day 36 Assessments, Day 57 Assessments, Day 78 Assessments, Moderate Intensity Exercise (9 wks), Moderate Intensity Exercise (one day), Placebo - Light Intensity Exercise (one day), Symptom Measures and Neuropsychological Tests; Other · Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 40 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes
Interventions: Empagliflozin 25 MG, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Biospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Alhambra, California • Beverly Hills, California • Burbank, California + 4 more

Conditions: Multiple Sclerosis, Pain, Sleep
Interventions: Cannabidiol (CBD), Placebo CBD, Placebo THC, Tetrahydrocannabinol (THC); Drug
Lead sponsor: Tiffany J. Braley, MD, MS; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cognitive Impairment, Ovarian Cancer
Interventions: N-Acetyl-Cysteine, Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Pain, Opioid Use Disorder
Interventions: CBD 300mg, CBD 600mg, Placebo 0mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Disorder
Interventions: Sham (placebo) TMS, Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 24 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Philadelphia, Pennsylvania

Conditions: Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Metastatic Esophageal Carcinoma
Interventions: Olanzapine, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pain
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
Interventions: Placebo, bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester); Other · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol-associated Hepatitis
Interventions: Acamprosate, IL-22, IL-22 (F-652) Placebo, Motivational Enhancement Therapy (MET), Motivational Interviewing (MI), Prednisone, Prednisone placebo, Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Cirrhosis, Frailty, Sarcopenia
Interventions: Creatine supplementation, HEAL-ME digital app, Placebo, Whey protein supplementation; Dietary Supplement · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer Weight Loss
Interventions: Placebo, TCMCB07; Drug
Lead sponsor: Endevica Bio; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Idiopathic Hypersomnia
Interventions: Placebo, TAK-360; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more

Conditions: Cancer, Cancers, Pain
Interventions: Oral cannabis THC/CBD, Oral cannabis high THC, Oral cannabis low THC, Placebo Comparator; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: E-cigarette Use, Withdrawal
Interventions: Placebo Nicotine Patch, Transdermal Nicotine Patch; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obstructive Sleep Apnea
Interventions: Acetazolamide, Atomoxetine and eszopiclone, Placebo, Trazodone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Myeloid Neoplasm
Interventions: Behavioral Placebo Control, GO-EXCAP Mobile App; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bronchopulmonary Dysplasia (BPD), Critical Illness, Premature Births
Interventions: Placebo, montelukast 4 mg granule; Drug
Lead sponsor: Duke University; Other
Eligibility: 7 Days to 28 Days
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Little Rock, Arkansas • Amherst, Massachusetts • Las Vegas, Nevada + 2 more

Conditions: Triglycerides
Interventions: Astaxanthin, Curcumin (Longvida™), Half Dose Curcumin (Longvida™), Placebo Control; Dietary Supplement · Other
Lead sponsor: Medinutra LLC; Other
Eligibility: 21 Years to 59 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, Ohio

Search by objective public record fields.

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

SGLT2i, Pioglitazone, and Ketone Production in T2D

Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females

Propranolol in Primary Progressive Aphasia

Childhood Trauma, Exercise, and Cognition

SGLTi, Hepatic Glucose Production and Ketogenesis

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Combined THC and CBD for OUD and Chronic Pain

Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Effects of Dronabinol in Opioid Maintained Patients

Effect of Ketone Esters on Liver Fat Content and Metabolic Function

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Impact of Daily Oral Cannabis Doses in Patients With Cancer

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Rescue Pharmacotherapy for OSA

A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms

PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation